Clinical Trials
18 trialsNCT05949632 2026-06-04
A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
Incyte Corporation
Phase 1/2 Terminated
NCT05579366 2026-06-03
RAINFOL-01
Genmab
Phase 1/2 Recruiting
NCT05417594 2026-06-02
CERTIS1
AstraZeneca
Phase 1/2 Recruiting
NCT05445778 2026-06-02
GLORIOSA
AbbVie
Phase 3 Active not recruiting
NCT05739981 2026-06-02
MRD
Imunon
Phase 1/2 Recruiting
NCT06024109 2026-06-02
BARHYSTER
Aesculap AG
Recruiting
NCT06619236 2026-06-02
RAINFOL-02
Genmab
Phase 3 Active not recruiting
NCT06915025 2026-06-02
OVATION-3
Imunon
Phase 3 Recruiting
NCT07024784 2026-06-02
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
AbbVie
Phase 2 Recruiting
NCT07604766 2026-06-02
RAINFOL-02
Genmab
Phase 3 Not yet recruiting
NCT07617753 2026-06-01
DUAL-OV-CAR-NK
Beijing Biotech
Phase 1/2 Recruiting
NCT06824467 2026-05-29
TroFuse-022
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06890338 2026-05-29
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
AbbVie
Phase 2 Recruiting
NCT07213804 2026-05-27
FRAmework-01
Eli Lilly and Company
Phase 3 Recruiting
NCT06682988 2026-05-26
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
AbbVie
Phase 2 Recruiting
NCT06161025 2026-05-22
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Daiichi Sankyo
Phase 2/3 Recruiting
NCT06787612 2026-05-20
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Regeneron Pharmaceuticals
Phase 2 Recruiting
NCT07402915 2026-05-20
Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
AstraZeneca
Phase 1 Recruiting